Silverback Therapeutics Stock Performance
| SPRY Stock | 14.29 0.03 0.21% |
The entity has a beta of 1.35, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Silverback Therapeutics will likely underperform. At this point, Silverback Therapeutics has a negative expected return of -0.18%. Please make sure to validate Silverback Therapeutics' kurtosis, and the relationship between the value at risk and rate of daily change , to decide if Silverback Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Silverback Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 210.5 M | |
| Free Cash Flow | -59.4 M |
Silverback |
Silverback Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,520 in Silverback Therapeutics on November 3, 2024 and sell it today you would lose (218.00) from holding Silverback Therapeutics or give up 14.34% of portfolio value over 90 days. Silverback Therapeutics is currently does not generate positive expected returns and assumes 3.8845% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Silverback, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Silverback Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Silverback Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Silverback Therapeutics, and traders can use it to determine the average amount a Silverback Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0455
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SPRY |
Estimated Market Risk
| 3.88 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Silverback Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Silverback Therapeutics by adding Silverback Therapeutics to a well-diversified portfolio.
Silverback Therapeutics Fundamentals Growth
Silverback Stock prices reflect investors' perceptions of the future prospects and financial health of Silverback Therapeutics, and Silverback Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Silverback Stock performance.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | (10.52) % | ||||
| Current Valuation | 1.18 B | ||||
| Shares Outstanding | 97.19 M | ||||
| Price To Book | 6.91 X | ||||
| Price To Sales | 540.80 X | ||||
| Revenue | 30 K | ||||
| EBITDA | (67.45 M) | ||||
| Total Debt | 274 K | ||||
| Book Value Per Share | 2.07 X | ||||
| Cash Flow From Operations | (59.27 M) | ||||
| Earnings Per Share | (0.50) X | ||||
| Total Asset | 233.19 M | ||||
| Retained Earnings | (131.3 M) | ||||
About Silverback Therapeutics Performance
Evaluating Silverback Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Silverback Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Silverback Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Silverback Therapeutics performance evaluation
Checking the ongoing alerts about Silverback Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Silverback Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Silverback Therapeutics generated a negative expected return over the last 90 days | |
| Silverback Therapeutics has high historical volatility and very poor performance | |
| Silverback Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 30 K. Net Loss for the year was (54.37 M) with loss before overhead, payroll, taxes, and interest of (14.71 M). | |
| Silverback Therapeutics generates negative cash flow from operations | |
| Silverback Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 68.0% of the company shares are owned by institutional investors |
- Analyzing Silverback Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Silverback Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Silverback Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Silverback Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Silverback Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Silverback Therapeutics' stock. These opinions can provide insight into Silverback Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Silverback Stock Analysis
When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.